HLS Therapeutics (74D) Stock Overview
A specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
74D Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
HLS Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.48 |
| 52 Week High | CA$3.40 |
| 52 Week Low | CA$2.04 |
| Beta | 0.83 |
| 1 Month Change | 11.71% |
| 3 Month Change | -0.80% |
| 1 Year Change | -23.93% |
| 3 Year Change | -27.06% |
| 5 Year Change | -78.43% |
| Change since IPO | -76.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| 74D | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 9.7% | -2.1% | -2.3% |
| 1Y | -23.9% | 42.4% | 4.8% |
Return vs Industry: 74D underperformed the German Pharmaceuticals industry which returned 41.8% over the past year.
Return vs Market: 74D underperformed the German Market which returned 3.4% over the past year.
Price Volatility
| 74D volatility | |
|---|---|
| 74D Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 74D's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 74D's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 85 | Craig Millian | www.hlstherapeutics.com |
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that are prescribed Clozaril; Nilemdo, a bempedoic acid product for cardiovascular risk reduction; Nexlizet, a bempedoic acid and ezetimibe product for cardiovascular risk reduction; and Vascepa, an icosapent ethyl capsule for the treatment of cardiovascular disease. It also distributes MyCare psychiatry lab assays, which are a line of tests that can be processed on analyzers used in laboratory systems to measure the blood levels of the most common antipsychotic drugs, including clozapine, risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone; and MyCare Insite, a point-of-care device that requires only a single drop of blood taken by a finger stick to measure patient drug levels.
HLS Therapeutics Inc. Fundamentals Summary
| 74D fundamental statistics | |
|---|---|
| Market cap | €79.93m |
| Earnings (TTM) | -€7.43m |
| Revenue (TTM) | €48.73m |
Is 74D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 74D income statement (TTM) | |
|---|---|
| Revenue | US$56.24m |
| Cost of Revenue | US$16.83m |
| Gross Profit | US$39.41m |
| Other Expenses | US$47.98m |
| Earnings | -US$8.57m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.28 |
| Gross Margin | 70.07% |
| Net Profit Margin | -15.24% |
| Debt/Equity Ratio | 74.6% |
How did 74D perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/15 16:06 |
| End of Day Share Price | 2026/09/15 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HLS Therapeutics Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Martin | Bloom Burton & Co. |
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Michael Freeman | Raymond James Ltd. |